Cargando…

(131)I-Labeled Anti-HER2 Nanobody for Targeted Radionuclide Therapy of HER2-Positive Breast Cancer

PURPOSE: The unique structure of nanobodies is advantageous for the development of radiopharmaceuticals for nuclear medicine. Nanobodies targeted to human epidermal growth factor receptor 2 (HER2) can be used as tools for the imaging and therapy of HER2-overexpressing tumors. In this study, we aimed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Lingzhou, Gong, Jiali, Qi, Qinli, Liu, Changcun, Su, Hongxing, Xing, Yan, Zhao, Jinhua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10094415/ https://www.ncbi.nlm.nih.gov/pubmed/37064291 http://dx.doi.org/10.2147/IJN.S399322

Ejemplares similares

Targeted Radionuclide Therapy with A (177)Lu-labeled Anti-HER2 Nanobody
por: D'Huyvetter, Matthias, et al.
Publicado: (2014)

(131)I-labeled polyethylenimine-entrapped gold nanoparticles for targeted tumor SPECT/CT imaging and radionuclide therapy
por: Sun, Na, et al.
Publicado: (2019)

Evaluation of an (131)I-labeled HER2-specific single domain antibody fragment for the radiopharmaceutical therapy of HER2-expressing cancers
por: Feng, Yutian, et al.
Publicado: (2022)

The Evolution of Targeted Radionuclide Diagnosis of HER2-Positive Breast Cancer
por: Bragina, O. D., et al.
Publicado: (2022)

Phenylboronic acid conjugated multifunctional nanogels with (131)I-labeling for targeted SPECT imaging and radiotherapy of breast adenocarcinoma
por: Kong, Lingdan, et al.
Publicado: (2022)

Advances in the Application of Radionuclide-Labeled HER2 Affibody for the Diagnosis and Treatment of Ovarian Cancer
por: Hu, Xianwen, et al.
Publicado: (2022)

Nanobody-Based Theranostic Agents for HER2-Positive Breast Cancer: Radiolabeling Strategies
por: Hrynchak, Ivanna, et al.
Publicado: (2021)

Combination of (131)I-trastuzumab and lanatoside C enhanced therapeutic efficacy in HER2 positive tumor model
por: Vinod, Nagarajan, et al.
Publicado: (2021)

(131)I-Labeled Multifunctional Polyethylenimine/Doxorubicin Complexes with pH-Controlled Cellular Uptake Property for Enhanced SPECT Imaging and Chemo/Radiotherapy of Tumors
por: Zhu, Jingyi, et al.
Publicado: (2021)

A Novel Small Molecular Antibody, HER2-Nanobody, Inhibits Tumor Proliferation in HER2-Positive Breast Cancer Cells In Vitro and In Vivo
por: Yan, Yan, et al.
Publicado: (2021)

(99m)Tc-labeled iRGD for single-positron emission computed tomography imaging of triple-negative breast cancer
por: Yu, Buhui, et al.
Publicado: (2022)

[(99m)Tc]Tc-Labeled Plectin-Targeting Peptide as a Novel SPECT Probe for Tumor Imaging
por: Gong, Jiali, et al.
Publicado: (2022)

Radionuclide I-131 Labeled Albumin-Paclitaxel Nanoparticles for Synergistic Combined Chemo-radioisotope Therapy of Cancer
por: Tian, Longlong, et al.
Publicado: (2017)

Targeting HER2-positive gastric cancer with a novel (18)F-labeled Z(HER2:342) probe
por: Pan, Yunyun, et al.
Publicado: (2019)

Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent?
por: Ishimine, Yu, et al.
Publicado: (2015)

Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors
por: Vorobyeva, Anzhelika, et al.
Publicado: (2018)

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
por: Horimoto, Yoshiya, et al.
Publicado: (2022)

HER2/positive and HER2/low in inflammatory breast cancer recurrence
por: Movchan, Oleksii Volodimirovich, et al.
Publicado: (2022)

HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer
por: Lipton, Allan, et al.
Publicado: (2013)

Delivery of the Radionuclide (131)I Using Cationic Fusogenic Liposomes as Nanocarriers
por: Kolašinac, Rejhana, et al.
Publicado: (2021)

Chlorotoxin peptide-functionalized polyethylenimine-entrapped gold nanoparticles for glioma SPECT/CT imaging and radionuclide therapy
por: Zhao, Lingzhou, et al.
Publicado: (2019)

Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer
por: Han, Sae-Won, et al.
Publicado: (2012)

HER2 Heterogeneity Is Associated with Poor Survival in HER2-Positive Breast Cancer
por: Hosonaga, Mari, et al.
Publicado: (2018)

HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer
por: Kaito, Akio, et al.
Publicado: (2019)

The impact of HER2-directed targeted therapy on HER2-positive DCIS of the breast
por: Lewis, Gary. D., et al.
Publicado: (2021)

Molecular Basis of HER2-Targeted Therapy for HER2-Positive Colorectal Cancer
por: Yoshikawa, Ayumu, et al.
Publicado: (2022)

Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer
por: Stanowicka-Grada, Malwina, et al.
Publicado: (2023)

Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
por: Ding, Yi, et al.
Publicado: (2018)

HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
por: Morsberger, Laura, et al.
Publicado: (2022)

Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
por: Atallah, N. M., et al.
Publicado: (2023)

Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients
por: Chen, Zhaoxu, et al.
Publicado: (2023)

Pre-Clinical Study of the [(18)F]AlF-Labeled HER2 Affibody for Non-Invasive HER2 Detection in Gastric Cancer
por: Han, Jingya, et al.
Publicado: (2022)

Progress and challenges in HER2-positive gastroesophageal adenocarcinoma
por: Zhao, Dan, et al.
Publicado: (2019)

Preclinical Targeted α- and β(−)-Radionuclide Therapy in HER2-Positive Brain Metastasis Using Camelid Single-Domain Antibodies
por: Puttemans, Janik, et al.
Publicado: (2020)

Antitumor activity of pan‐HER inhibitors in HER2‐positive gastric cancer
por: Yoshioka, Takahiro, et al.
Publicado: (2018)

HER2-positive gastric cancer
por: Boku, Narikazu
Publicado: (2013)

Reviving a Classic Antigen with a Cutting-Edge Approach: Nanobodies for HER2+ Breast Cancer
por: Castrignano, Chiara, et al.
Publicado: (2023)

Expression of CD24 is associated with HER2 expression and supports HER2-Akt signaling in HER2-positive breast cancer cells
por: Hosonaga, Mari, et al.
Publicado: (2014)

Incidence and prognostic impact of HER2‐positivity loss after dual HER2‐directed neoadjuvant therapy for HER2+ breast cancer
por: LeVee, Alexis, et al.
Publicado: (2023)

Next-generation sequencing, should I use anti-HER2 therapy for HER2-amplified tumors off-label? Illustrating an extrapolation framework
por: Cho, Doah, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_va9nict7ralk2e9l1pe5c1u26k